Details

Autor(en) / Beteiligte

• Rabaan, Ali A.
• Abas, Abdul Hawil
• Tallei, Trina Ekawati
• Al‐Zaher, Mona A.
• Al‐Sheef, Noor M.
• Fatimawali
• Al‐Nass, Esraa Z.
• Al‐Ebrahim, Eba A.
• Effendi, Yunus
• Idroes, Rinaldi
• Alhabib, Mather F.
• Al‐Fheid, Hussain A.
• Adam, Ahmad Akroman
• Bin Emran, Talha

Titel

Monkeypox outbreak 2022: What we know so far and its potential drug targets and management strategies

Ist Teil von

• Journal of medical virology, 2023-01, Vol.95 (1), p.e28306-n/a

Ort / Verlag

United States: Wiley Subscription Services, Inc

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Monkeypox is a rare zoonotic disease caused by infection with the monkeypox virus. The disease can result in flu‐like symptoms, fever, and a persistent rash. The disease is currently spreading throughout the world and prevention and treatment efforts are being intensified. Although there is no treatment that has been specifically approved for monkeypox virus infection, infected patients may benefit from using certain antiviral medications that are typically prescribed for the treatment of smallpox. The drugs are tecovirimat, brincidofovir, and cidofovir, all of which are currently in short supply due to the spread of the monkeypox virus. Resistance is also a concern, as widespread replication of the monkeypox virus can lead to mutations that produce monkeypox viruses that are resistant to the currently available treatments. This article discusses monkeypox disease, potential drug targets, and management strategies to overcome monkeypox disease. With the discovery of new drugs, it is hoped that the problem of insufficient drugs will be resolved, and it is not anticipated that drug resistance will become a major issue in the near future.